Finding novel drugs based on the understanding of a target tissue is called Drug design. Drug design, in its most basic form, is creating molecules that are complementary in charge and shape to the target molecule by which drugs interact and bind. In the big data age, drug design commonly but not always depends on computer modelling methods and bioinformatics strategies. Biopharmaceuticals, particularly therapeutic antibodies, are a class of drugs that are becoming more and more significant in addition to small molecules, and computational methods have made significant strides in enhancing the affinity, selectivity, and stability of these protein-based therapeutics [3]. Preclinical research using animal and cell-based models, human clinical trials, and then the last phase of securing regulatory approval to sell the medicine make up drug development and discovery. The process of modern drug development includes the identification of screening hits, medicinal chemistry, and optimization of those hits to enhance their affinity, efficacy/potency, metabolic stability (to lengthen the half-life), and oral bioavailability. Prior to clinical trials, medication development will start after a molecule that satisfies all of these criteria has been found.
Vladlen Slepak
University of Miami School of Medicine, United States
Axel H Schonthal
University of Southern California, United States
Bernd Blobel
University of Regensburg, Germany
Consolato M Sergi
University of Alberta, Canada
Luis Jesus Villarreal Gomez
Universidad Autónoma de Baja California, Mexico
Lan Wang
Paretor LLC, United States
Maria Cristina Gamberini
University of Modena and Reggio Emilia, Italy
Lucas Amaral Machado
University of Sao Paulo State – UNESP, Brazil
Saad Tayyab
UCSI University, Malaysia
Anil Pareek
Anand Pharmacy College, IndiaSubmit your abstract Today
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami School of Medicine, United States
Title : Application of quality by design for pulmonary liposomes: Preliminary study to nano in-microparticle
Lucas Amaral Machado, University of Sao Paulo State – UNESP, Brazil
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : Design and characterization of gum arabic buccal films for protein drug delivery
Krisztian Pamlenyi, University of Szeged, Hungary
Title : Tailored cellular environments to enable drug design
Lan Wang, Paretor LLC, United States
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, InMedStar and Biona, Russian Federation
Title : Rational optimization of antibody–cyanine bioconjugates for targeted theranostic drug delivery and photo/sono activation
Amartya Sanyal, Ariel University, Israel
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : From in silico design to xenograft validation: Synthesis and evaluation of an Anti-EGFR antibody-derived peptide-drug conjugate for NSCLC
Pousali Mitra, Ariel University, Israel